| Window | Theses | Resolved | Wins | Win rate | Avg return | Median return |
|---|---|---|---|---|---|---|
| 1d | — | — | — | — | — | — |
| 3d | — | — | — | — | — | — |
| 1w | — | — | — | — | — | — |
| 1m | — | — | — | — | — | — |
| 3m | — | — | — | — | — | — |
| 6m | — | — | — | — | — | — |
| 1y | — | — | — | — | — | — |
Past performance does not predict future results. Informational only, not investment advice.
Viatris trades at 5.5x forward P/E after restructuring into a specialty pharma and high-barrier generics player. MR-141 for presbyopia (FDA decision October) targets 90% of US adults over 45 with massive TAM, while aggressive hiring signals confidence in growth execution.
Lithia Motors trades at ~8.9x forward P/E with high-margin financing arm (Driveway Finance) turning profitable and guiding toward $150-200M annual—a recurring revenue stream bolted onto retail operations. Morningstar fair value of $387 vs. current $270 suggests 43% upside, supported by management share buybacks and analyst buy ratings.
Lennar trades at ~7x forward P/E with a structural supply deficit of 4 million homes supporting pricing power and new builds as primary supply. Strong balance sheet ($2.1B cash, <15% debt-to-capital), improving inventory turns, and falling construction costs position the company for margin expansion ahead of spring selling season.
End of results.